A Randomised Open-label Phase II Trial of Consolidation with Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms STIMULI
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
- 07 Oct 2015 New drug added in the trial (Nivolumab) as reported by ClinicalTrials.gov record.
- 07 Oct 2015 Planned End Date changed from 1 Apr 2020 to 1 Jan 2022 as reported by ClinicalTrials.gov record.